Samsca Related Clinical Trials
Post-Authorisation Safety Study of Samsca (Tolvaptan) Used in Routine Medical Practice [Active, not recruiting]
Effects of Tolvaptan in Healthy Adults [Recruiting]
A PK Study of 3 Dosages of Tolvaptan in Patients With Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH) [Completed]
Effects of Tolvaptan vs Fluid Restriction in Hospitalized Subjects With Dilutional Hyponatremia [Terminated]
Effect of the Aquaretic Tolvaptan on Nitric Oxide System. A Dose-response Study (DOVA) [Active, not recruiting]
Phase III Study of Tolvaptan Tablet to Treat Cirrhosis Ascites [Completed]
Study of the Safety and Effectiveness of SAMSCAŽ (Tolvaptan) in Children and Adolescents With Euvolemic or Hypervolemic Hyponatremia [Recruiting]
A Trial of Tolvaptan in Children and Adolescent Subjects With Euvolemic and Hypervolemic Hyponatremia [Not yet recruiting]
Tolvaptan For Worsening Outpatient Heart Failure: Role of Copeptin In Identifying Responders [Not yet recruiting]
Tolvaptan for Ascites in Cirrhotic Patients [Completed]
Bioavailability Study Comparing Tolvaptan Administered Via Nasogastric Tube to Tolvaptan Tablets Swallowed Intact [Completed]
Effect of the Aquaretic Tolvaptan on Nitric Oxide System [Recruiting]
Efficacy and Safety of Tolvaptan in Cirrhotic Patients With Hyponatremia [Completed]
Randomized, Double-Blind, Placebo Controlled Study of the Short Term Clinical Effects of Tolvaptan in Patients Hospitalized for Worsening Heart Failure With Challenging Volume Management [Recruiting]
Dose Exploring and Setting Study for Tolvaptan to Treat Hepatic Cirrhosis With Ascites [Completed]
Tolvaptan in Hyponatremic Cancer Patients [Completed]
Acute Heart Failure Patients With High Copeptin Treated With Tolvaptan Targets Increased AVP Activation for Treatment (ACTIVATE) [Not yet recruiting]
Targeting Acute Congestion With Tolvaptan in Congestive Heart Failure [Recruiting]
8-Week Study of Tolvaptan Dose Forms in Autosomal Dominant Polycystic Kidney Disease (ADPKD) [Completed]
Efficacy and Safety of Tolvaptan in the Treatment of Cardiac-Induced Edema in Patients With Heart Failure [Completed]
A Trial to Investigate the Efficacy and Safety of Orally Administered Tolvaptan (OPC-41061) in Patients With Chronic Renal Failure Undergoing Hemodialysis or Hemodiafiltration [Recruiting]
Dose-finding Study of New Tolvaptan Formulation in Subjects With ADPKD [Completed]
Role of Midodrine and Tolvaptan in Patients With Cirrhosis With Refractory or Recurrent Ascites [Recruiting]
Open-Label Tolvaptan Study in Subjects With ADPKD [Active, not recruiting]
Pilot Study of Using Copeptin to Predict Response to Tolvaptan [Completed]
Efficacy and Safety Study of Tolvaptan to Treat Patients With Cardiac Edema [Completed]
A Study to Investigate Pharmacodynamics and Pharmacokinetics of OPC-41061 in Patients With Hepatic Edema [Completed]
Effect of Tolvaptan on Cognitive Function in Cirrhosis [Completed]
Pharmacokinetics and Clinical Response of Tolvaptan in Neurocritical Care Patients [Recruiting]
Tolvaptan Phase 3 Efficacy and Safety Study in ADPKD [Completed]
Effect of Tolvaptan on Mid- to Long-term Prognosis of Heart Failure Patients [Completed]
Effect of the Aquaretic Tolvaptan on Nitric Oxide System (TORA) [Completed]
Use of Tolvaptan to Reduce Urinary Supersaturation: a Pilot Proof of Principle Study [Active, not recruiting]
Tolvaptan Open-Label Pilot Efficacy, Tolerability and Safety Study in ADPKD [Completed]
A Trial to Investigate the Efficacy of OPC-41061 Administered at a Dose of 7.5 mg in Patients With Hepatic Edema [Completed]
Efficacy and Safety of Tolvaptan in Subjects With Chronic Kidney Disease Between Late Stage 2 to Early Stage 4 Due to Autosomal Dominant Polycystic Kidney Disease [Recruiting]
Tolvaptan for Hyponatremia in Cirrhotic Patients With Ascites [Not yet recruiting]
Tolvaptan/Ultrafiltration in the Treatment of Acute Heart Failure [Recruiting]
Tolvaptan for In-hospital Hyponatremia [Terminated]
Tolvaptan to Reduce Length of Stay in Hospitalized Patients With Cirrhosis and Hyponatremia [Terminated]
Outcome and Treatment Quality Study of Tolvaptan to Treat Hyponatremia in Patients With Heart Failure [Recruiting]
A Long-term Administration Study of OPC-41061 in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) (2) [Extension of Study 156-05-002] [Active, not recruiting]
A Double-blind, Placebo-controlled Study of OPC-41061 in the Treatment of Cardiac Edema (Congestive Heart Failure) [Completed]
A Trial of OPC-41061 in Patients With Hepatic Edema - Investigation of the Safety of Treatment at 7.5 mg Beyond 7 Days and of the Effect of Dose Escalation to 15 mg [Completed]
Effect of Samsca on Control of Hyponatremia and Extracellular Fluid in Cirrhotic Patients With Ascites [Recruiting]
A Dose-defining Study of OPC-41061 in Treatment of Hepatic Edema [Completed]
Short-Term Renal Hemodynamic Effects of Tolvaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease (ADPKD) [Completed]
Efficacy and Safety of Tolvaptan in Japanese Patients With Acute Heart Failure [Active, not recruiting]
The Use of Tolvaptan to Prevent Renal Dysfunction in High Risk Patients With Heart Failure-Pilot Study [Withdrawn]
Open-label Dose-finding Trial of OPC-41061 in Patients With Chronic Renal Failure Undergoing Peritoneal Dialysis [Completed]
Efficacy and Safety Study of the Tolvaptan Tablets in Patients With Non-hypovolemic Non-acute Hyponatremia [Recruiting]
Pharmacokinetics/Pharmacodynamics (PK/PD) Characteristics of Tolvaptan Tablet in Korean Healthy Male [Completed]
Open-label Trial to Evaluate the Long Term Safety of Titrated Immediate-release Tolvaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease [Enrolling by invitation]
International, Multicenter, Study of One-year, Open-label, Titrated Oral Tolvaptan Tablet Administration in Patients With Chronic Hyponatremia [Completed]
A Clinical Pharmacological Study of OPC-41061 in the Treatment of Cardiac Edema (Congestive Heart Failure) [Completed]
A Dose-finding Study of OPC-41061 in Treatment of Cardiac Edema (Congestive Heart Failure) [Completed]
Effects of Titrated Oral Tolvaptan 15-60 mg Once Daily (QD) on Cognitive and Neurological Function in Elderly Hyponatremic Patients [Completed]
A Phase 2 Efficacy and Safety Study of the Tolvaptan Tablets in Patients With Non-hypovolemic Non-acute Hyponatremia [Completed]
Aquaresis Utility for Hyponatremic Acute Heart Failure Study [Not yet recruiting]
|